These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 9350994

  • 1. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1.
    Gils A, Lu J, Aertgeerts K, Knockaert I, Declerck PJ.
    FEBS Lett; 1997 Sep 29; 415(2):192-5. PubMed ID: 9350994
    [Abstract] [Full Text] [Related]

  • 2. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
    Vleugels N, Leys J, Knockaert I, Declerck PJ.
    J Pharm Belg; 2000 Sep 29; 55(2):57-8. PubMed ID: 10842928
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
    Gils A, Knockaert I, Declerck PJ.
    Biochemistry; 1996 Jun 11; 35(23):7474-81. PubMed ID: 8652525
    [Abstract] [Full Text] [Related]

  • 5. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
    Lawrence DA, Olson ST, Palaniappan S, Ginsburg D.
    Biochemistry; 1994 Mar 29; 33(12):3643-8. PubMed ID: 8142362
    [Abstract] [Full Text] [Related]

  • 6. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
    Wang Q, Shaltiel S.
    BMC Biochem; 2003 Jul 08; 4():5. PubMed ID: 12848892
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.
    Gils A, Declerck PJ.
    J Biol Chem; 1997 May 09; 272(19):12662-6. PubMed ID: 9139722
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The importance of helix F in plasminogen activator inhibitor-1.
    Vleugels N, Gils A, Bijnens AP, Knockaert I, Declerck PJ.
    Biochim Biophys Acta; 2000 Jan 03; 1476(1):20-6. PubMed ID: 10606763
    [Abstract] [Full Text] [Related]

  • 14. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule.
    Sui GC, Wiman B.
    Biochem J; 1998 Apr 15; 331 ( Pt 2)(Pt 2):409-15. PubMed ID: 9531478
    [Abstract] [Full Text] [Related]

  • 15. Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties.
    De Taeye B, Compernolle G, Dewilde M, Biesemans W, Declerck PJ.
    J Biol Chem; 2003 Jun 27; 278(26):23899-905. PubMed ID: 12686544
    [Abstract] [Full Text] [Related]

  • 16. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L, Martensen PM, Sottrup-Jensen L, Justesen J, Rodenburg KW, Andreasen PA.
    Eur J Biochem; 1996 Oct 01; 241(1):38-46. PubMed ID: 8898886
    [Abstract] [Full Text] [Related]

  • 17. Structural determinants in the stability of the serpin/proteinase complex.
    De Taeye B, Verbeke K, Compernolle G, Biesemans W, Gils A, Declerck PJ.
    Biochem Biophys Res Commun; 2003 Aug 01; 307(3):529-34. PubMed ID: 12893254
    [Abstract] [Full Text] [Related]

  • 18. The Bbeta-sheet in the PAI-1 molecule plays an important role for its stability.
    Sui GC, Wiman B.
    Thromb Haemost; 2000 Jun 01; 83(6):896-901. PubMed ID: 10896245
    [Abstract] [Full Text] [Related]

  • 19. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW, Andreasen PA.
    Eur J Biochem; 1997 Sep 15; 248(3):775-85. PubMed ID: 9342229
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.